Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Authors
Keywords
-
Journal
Biomedicines
Volume 10, Issue 2, Pages 274
Publisher
MDPI AG
Online
2022-01-27
DOI
10.3390/biomedicines10020274
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The protective effects of trelagliptin on high‐fat diet‐induced nonalcoholic fatty liver disease in mice
- (2021) Guang Wang et al. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
- (2021) Qi Pan et al. EBioMedicine
- Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial
- (2021) Salomon M. Stemmer et al. Cancers
- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment
- (2021) Ming Yang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
- (2021) Sachiko Hattori et al. Diabetology & Metabolic Syndrome
- Alternative RNA Splicing in Fatty Liver Disease
- (2021) Panyisha Wu et al. Frontiers in Endocrinology
- GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
- (2021) K. El et al. Science Advances
- Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
- (2021) Masato Yoneda et al. BMJ Open Diabetes Research & Care
- What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?
- (2021) Masato Yoneda et al. EXPERT OPINION ON PHARMACOTHERAPY
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial
- (2021) Samer Gawrieh et al. HEPATOLOGY
- Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double‐blind controlled trial
- (2021) Khadija A. M. Glal et al. Journal of Hepato-Biliary-Pancreatic Sciences
- FXR agonists for NASH: How are they different and what difference do they make?
- (2021) Claus Kremoser JOURNAL OF HEPATOLOGY
- Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis
- (2021) Virender Kumar et al. ADVANCED DRUG DELIVERY REVIEWS
- FXR in liver physiology: Multiple faces to regulate liver metabolism
- (2021) Katrin Panzitt et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
- (2021) Stephen A. Harrison et al. Nature Communications
- Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
- (2021) Julia M Fraile et al. Drug Design Development and Therapy
- Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice
- (2021) Fengfeng Li et al. Acta Pharmaceutica Sinica B
- Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury
- (2021) Yun-Cheng Hsieh et al. Cells
- Semaglutide for nonalcoholic steatohepatitis: closer to a solution?
- (2021) Christina Liava et al. Hepatobiliary Surgery and Nutrition
- Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
- (2021) Kenneth Cusi et al. Lancet Gastroenterology & Hepatology
- Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐ aspartate aminotransferase score
- (2021) Takeshi Hatanaka et al. JGH Open
- Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis
- (2021) Rifaat Safadi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Protective effect of SGL5213, a potent intestinal sodium–glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice
- (2021) Yasushi Honda et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
- (2021) V. Ratziu et al. NATURE MEDICINE
- ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
- (2021) Roberto A. Calle et al. NATURE MEDICINE
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- (2021) Sven M. Francque et al. NEW ENGLAND JOURNAL OF MEDICINE
- A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
- (2021) Samit Ghosal et al. Scientific Reports
- Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis
- (2021) Yang An et al. Frontiers in Medicine
- Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: From Molecular Mechanisms to Clinical Applications
- (2021) Wenjing Zai et al. Biomedicines
- Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
- (2020) K.J. Lucas et al. DIGESTIVE AND LIVER DISEASE
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A
- (2020) Bin Teng et al. JOURNAL OF HEPATOLOGY
- Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects
- (2020) Mitsuhiro Kawakubo et al. Scientific Reports
- Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis
- (2020) Diletta Overi et al. Cells
- Effect of ursodeoxycholic acid on liver markers: A systematic review and meta‐analysis of randomized placebo‐controlled clinical trials
- (2020) Mario Simental‐Mendía et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- G-Protein-Coupled Receptors 120 Agonist III Improves Hepatic Inflammation and ER Stress in Steatohepatitis
- (2020) Xiaoyuan Chen et al. DIGESTIVE DISEASES AND SCIENCES
- Sirtuins: potential therapeutic targets for regulating acute inflammatory response?
- (2020) Vidula Vachharajani et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis
- (2020) Wei Chen et al. HEPATOLOGY
- Genetic pathways in nonalcoholic fatty liver disease: Insights from systems biology
- (2020) Silvia Sookoian et al. HEPATOLOGY
- A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
- (2020) Ping An et al. LIVER INTERNATIONAL
- LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis
- (2020) Mordehay Klepfish et al. Frontiers in Immunology
- The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis
- (2020) Tobias Puengel et al. Journal of Clinical Medicine
- EX-527 Prevents the Progression of High-Fat Diet-Induced Hepatic Steatosis and Fibrosis by Upregulating SIRT4 in Zucker Rats
- (2020) Amit Kundu et al. Cells
- Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts
- (2020) Yingying Cui et al. Cells
- Evolving role for pharmacotherapy in NAFLD/NASH
- (2020) Suzanna L. Attia et al. CTS-Clinical and Translational Science
- 1804-P: HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA–Induced Liver Inflammation and Fibrosis Mice
- (2020) JUNG KUK KIM et al. DIABETES
- 115-LB: Oral Insulin–Induced Reduction in Liver Fat Content in T2DM Patients with Nonalcoholic Steatohepatitis
- (2020) MIRIAM KIDRON et al. DIABETES
- Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease
- (2020) Estefanía de Gregorio et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The roles of galectins in hepatic diseases
- (2020) Mei-Juan Sun et al. JOURNAL OF MOLECULAR HISTOLOGY
- The GPR40 full agonist SCO-267 improves liver parameters in a mouse model of nonalcoholic fatty liver disease without affecting glucose or body weight
- (2020) Mitsugi Ookawara et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease
- (2020) Jean-Christophe Simard et al. Scientific Reports
- Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers
- (2020) John Climax et al. Journal of the American Heart Association
- Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
- (2020) Silvina Gallo et al. Diabetes Therapy
- Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
- (2020) Rohit Loomba et al. Lancet Gastroenterology & Hepatology
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2020) Hoda Taheri et al. ADVANCES IN THERAPY
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study
- (2020) Jorge Luis Poo et al. Hepatology International
- EDP-297, a novel and potent fxr agonist, exhibit robust anti-fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis
- (2020) Mozhdeh Sojoodi et al. JOURNAL OF HEPATOLOGY
- Synergistic effect of clostridium butyricum miyairi on rifaximin in mice model of non-alcoholic steatohepatitis by methionine choline-deficient diet
- (2020) Ryo Yamauchi et al. JOURNAL OF HEPATOLOGY
- Co-administration of PF-05221304 and PF-06865571 delivers robust whole liver fat reduction and mitigation of acetyl-coa carboxilase inhibitor induced hypertriglyceridemia in patients with NAFLD
- (2020) Roberto Calle et al. JOURNAL OF HEPATOLOGY
- Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis
- (2020) Cheng-Han Lee et al. Nutrients
- Mitochondrial Transfer by Human Mesenchymal Stromal Cells Ameliorates Hepatocyte Lipid Load in a Mouse Model of NASH
- (2020) Mei-Ju Hsu et al. Biomedicines
- Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
- (2020) Omesh Goyal et al. Scientific Reports
- FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
- (2020) Emma Henriksson et al. Frontiers in Endocrinology
- Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies
- (2020) Carmelo Luci et al. Frontiers in Endocrinology
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis
- (2020) Lucas Ribeiro dos Santos et al. CURRENT DIABETES REVIEWS
- The utility of ezetimibe therapy in nonalcoholic fatty liver disease
- (2019) Baek Gyu Jun et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data
- (2019) Juan-Juan Li et al. Revista da Associacao Medica Brasileira
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
- (2019) Yan‐Ling He et al. DIABETES OBESITY & METABOLISM
- Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Non-Alcoholic Steatohepatitis
- (2019) Anissa A. Widjaja et al. GASTROENTEROLOGY
- LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
- (2019) Rohit Loomba et al. JOURNAL OF HEPATOLOGY
- 1029-P: Teneligliptin Significantly Reduces Liver Fat Content (LFC) and Delays Progression of NASH in Type 2 Diabetes Mellitus Patients
- (2019) VISHAL KUMAR GUPTA DIABETES
- Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease
- (2019) Sang Bong Ahn et al. Scientific Reports
- Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes
- (2019) Peili Wu et al. HORMONE AND METABOLIC RESEARCH
- The Role of Thyroid Hormones in Hepatocyte Proliferation and Liver Cancer
- (2019) Fabio Gionfra et al. Frontiers in Endocrinology
- First‐in‐class fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities
- (2019) Majid M. Syed‐Abdul et al. HEPATOLOGY
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
- (2019) Sravan K. Thondam et al. PEPTIDES
- The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies
- (2019) Marica Meroni et al. Nutrients
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
- (2019) Naga Chalasani et al. GASTROENTEROLOGY
- Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
- (2019) Joost Boeckmans et al. Cells
- Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease
- (2018) N. Chalasani et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
- (2018) K. Cusi et al. DIABETIC MEDICINE
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients
- (2018) Michiharu Komatsu et al. HEPATOLOGY RESEARCH
- The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
- (2018) Laura Iogna Prat et al. Hormones-International Journal of Endocrinology and Metabolism
- A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial
- (2018) Journal of Gastrointestinal and Liver Diseases
- Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model
- (2018) R. Walczak et al. JOURNAL OF HEPATOLOGY
- Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH
- (2018) Daniela Carmen Oniciu et al. PLoS One
- INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
- (2018) Jonathan D Roth et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease
- (2018) Mohammad Zarei et al. Molecular Metabolism
- Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
- (2018) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Hepatic thyroid hormone receptor β1 agonism: good for lipids, good for bile?
- (2018) Paul A. Dawson et al. JOURNAL OF LIPID RESEARCH
- Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease
- (2018) Jian-Hui Yan et al. MEDICINE
- The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis
- (2018) Heidi Schilter et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
- (2018) Ji-Won Kim et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- (2017) Chris Estes et al. HEPATOLOGY
- Compact bone-derived mesenchymal stem cells attenuate nonalcoholic steatohepatitis in a mouse model by modulation of CD4 cells differentiation
- (2017) Huafeng Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
- (2017) Yong-ho Lee et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents
- (2017) Fatemeh Famouri et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Antioxidant dietary approach in treatment of fatty liver: New insights and updates
- (2017) Alessandra Ferramosca et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Improvement of non-alcoholic steatohepatitis by hepatocyte-like cells generated from iPSCs with Oct4/Sox2/Klf4/Parp1
- (2017) Yueh Chien et al. Oncotarget
- Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH – Proteomic and lipidomic insight
- (2017) Lívia Samara dos Reis Rodrigues Okada et al. CLINICAL NUTRITION
- BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
- (2017) Adriana Carino et al. Scientific Reports
- Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
- (2016) Monize Aydar Nogueira et al. CLINICAL NUTRITION
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis
- (2016) Xiaoyun Wei et al. Evidence-based Complementary and Alternative Medicine
- Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials
- (2016) Xiaolin Gao et al. HEPATOLOGY RESEARCH
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Sirtuins and nonalcoholic fatty liver disease
- (2016) Fatiha Nassir et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
- (2016) Xi-Xi He et al. PLoS One
- Heat Killed Lactobacillus reuteri GMNL-263 Reduces Fibrosis Effects on the Liver and Heart in High Fat Diet-Hamsters via TGF-β Suppression
- (2015) Wei-Jen Ting et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- An Insulin-Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss
- (2015) Tomohiro Fukunaga et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Eicosapentaenoic Acid Ameliorates Non-Alcoholic Steatohepatitis in a Novel Mouse Model Using Melanocortin 4 Receptor-Deficient Mice
- (2015) Kuniha Konuma et al. PLoS One
- Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis
- (2014) A. Alisi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice
- (2014) Jinge Xin et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C
- (2014) Lucia Flores-Contreras et al. BMC GASTROENTEROLOGY
- Osteocalcin Protects Against Nonalcoholic Steatohepatitis in a Mouse Model of Metabolic Syndrome
- (2014) Anisha A. Gupte et al. ENDOCRINOLOGY
- Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation
- (2014) Takara L. Stanley et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease
- (2014) S. Nabavi et al. JOURNAL OF DAIRY SCIENCE
- Thyroid hormone receptors and resistance to thyroid hormone disorders
- (2014) Tânia M. Ortiga-Carvalho et al. Nature Reviews Endocrinology
- Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
- (2014) Xing-Chun Wang WORLD JOURNAL OF GASTROENTEROLOGY
- Lactobacillus plantarum NCU116 improves liver function, oxidative stress and lipid metabolism in rats with high fat diet induced non-alcoholic fatty liver disease
- (2014) Chuan Li et al. Food & Function
- Metabolic regulation of Sirtuins upon fasting and the implication for cancer
- (2013) Yueming Zhu et al. CURRENT OPINION IN ONCOLOGY
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- The TGR5 receptor mediates bile acid–induced itch and analgesia
- (2013) Farzad Alemi et al. JOURNAL OF CLINICAL INVESTIGATION
- Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis
- (2013) Thomas Klein et al. Medical Molecular Morphology
- SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease
- (2013) Yasar Colak et al. MEDICAL SCIENCE MONITOR
- Sirtuins in stress response: guardians of the genome
- (2013) L Bosch-Presegué et al. ONCOGENE
- Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
- (2013) Yongjie Ma et al. PHARMACEUTICAL RESEARCH
- Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease
- (2013) Peter G. Traber et al. PLoS One
- Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
- (2013) Yan-Yan Ma WORLD JOURNAL OF GASTROENTEROLOGY
- Action and therapeutic potential of oxyntomodulin
- (2013) Alessandro Pocai Molecular Metabolism
- Review article: a comparison of glucagon-like peptides 1 and 2
- (2012) P. Janssen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2
- (2012) Jenson Qi et al. JOURNAL OF LIPID RESEARCH
- Toll-Like Receptors in Liver Fibrosis: Cellular Crosstalk and Mechanisms
- (2012) Ling Yang et al. Frontiers in Physiology
- Effects and mechanisms of berberine in diabetes treatment
- (2012) Jun Yin et al. Acta Pharmaceutica Sinica B
- Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial
- (2011) V. Nobili et al. ARCHIVES OF DISEASE IN CHILDHOOD
- Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial
- (2011) S. L. Samson et al. DIABETOLOGIA
- Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis
- (2011) Michele Malaguarnera et al. DIGESTIVE DISEASES AND SCIENCES
- Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome
- (2011) Yoshiyuki Sasaki et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome
- (2011) Marcelo Ezquer et al. JOURNAL OF HEPATOLOGY
- Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2011) Helen M. Parker et al. JOURNAL OF HEPATOLOGY
- Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease
- (2011) Pietro Vajro et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet
- (2011) Ryuichi Morishita Molecular Medicine Reports
- Fatty Acid Bile Acid Conjugate Inhibits Hepatic Stearoyl Coenzyme A Desaturase and Is Non-atherogenic
- (2010) Alicia Leikin-Frenkel et al. ARCHIVES OF MEDICAL RESEARCH
- Role of thyroid receptor β in lipid metabolism
- (2010) Camilla Pramfalk et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started